ERBB2 and breast carcinoma: In a preclinical study, [(HER2)2xCD16] was superior to trastuzumab in triggering γδ T cell and NK cell-mediated lysis of HER2-expressing cancers, such as pancreatic ductal adenocarcinoma breast cancer, and autologous primary ovarian tumor cells (51).